Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of April 2026, specifically dated April 2, 2026. The report addresses a regulatory notice received from the Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a listing deficiency and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq. The company failed to comply with Nasdaq Listing Rule 5550(a)(2), which requires ordinary shares to maintain a closing bid price of at least $1.00 per share.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or general business risks. The primary contingency identified is the potential loss of Nasdaq listing status if the bid price deficiency is not remediated within the timeframe allowed by Nasdaq rules.
Investor Verification Checklist
- Verify the current closing bid price of Evogene Ltd. shares to assess the severity of the deficiency.
- Review the attached press release (Exhibit 99.1) for specific details on the cure period granted by Nasdaq.
- Monitor subsequent filings for announcements regarding a plan to regain compliance, such as a reverse stock split.
- Check for any trading halts or delisting proceedings initiated by Nasdaq following this notice.